期刊
JOURNAL OF CLINICAL INVESTIGATION
卷 129, 期 1, 页码 12-23出版社
AMER SOC CLINICAL INVESTIGATION INC
DOI: 10.1172/JCI122955
关键词
-
资金
- British Heart Foundation (BHF)
- Wellcome Trust
- Medical Research Council (MRC)
- BHF [RG/13/18/30563]
- Deutsche Forschungsgemeinschaft [SFB/TR240]
- Rudolf Virchow Center
Although platelets are best known for their role in hemostasis, they are also crucial in development, host defense, inflammation, and tissue repair. Many of these roles are regulated by the immune-like receptors glycoprotein VI (GPVI) and C-type lectin receptor 2 (CLEC-2), which signal through an immunoreceptor tyrosine-based activation motif (ITAM). GPVI is activated by collagen in the subendothelial matrix, by fibrin and fibrinogen in the thrombus, and by a remarkable number of other ligands. CLEC-2 is activated by the transmembrane protein podoplanin, which is found outside of the vasculature and is upregulated in development, inflammation, and cancer, but there is also evidence for additional ligands. In this Review, we discuss the physiological and pathological roles of CLEC-2 and GPVI and their potential as targets in thrombosis and thromboinflammatory disorders (i.e., disorders in which inflammation plays a critical role in the ensuing thrombosis) relative to current antiplatelet drugs.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据